In multiple myeloma, the overexpression of receptor activator of nuclear factor kappa B (NF-jB) ligand (RANKL) leads to the induction of NF-jB and activator protein-1 (AP-1)-related osteoclast activation and enhanced bone resorption. The purpose of this study was to examine the molecular and functional effects of proteasome inhibition in RANKL-induced osteoclastogenesis. Furthermore, we aimed to compare the outcome of proteasome versus selective NF-jB inhibition using bortezomib (PS-341) and I-jB kinase inhibitor PS-1145. Primary human osteoclasts were derived from CD14 þ precursors in presence of RANKL and macrophage colony-stimulating factor (M-CSF). Both bortezomib and PS-1145 inhibited osteoclast differentiation in a dose-and time-dependent manner and furthermore, the bone resorption activity of osteoclasts. The mechanisms of action involved in early osteoclast differentiation were found to be related to the inhibition of p38 mitogenactivated protein kinase pathways, whereas the later phase of differentiation and activation occurred due to inhibition of p38, AP-1 and NF-jB activation. The AP-1 blockade contributed to significant reduction of osteoclastic vascular endothelial growth factor production. In conclusion, our data demonstrate that proteasomal inhibition should be considered as a novel therapeutic option of cancer-induced lytic bone disease.
Introduction
Bone remodeling is a phenomenon that occurs under physiological conditions, whereas a strong coordination between bone formation managed by osteoblasts and bone degradation managed by osteoclasts ensures the bone homeostasis. Under pathological conditions that lead to enhanced bone degradation, the balance is shifted in favor of osteoclasts. 1, 2 That imbalance may result in formation of lytic bone lesions, bone pain, pathological fractures, hypercalcemia and reduced quality of life. 3 In cancer, enhanced osteoclast activation might occur by direct contact between tumor cells and osteoclastic precursors or by soluble factors within the bone marrow microenvironment. They are summarized by osteoclast-activating factors (OAFs) and might be produced by tumor cells or by stromal cells in response to tumor cells. 4, 5 The most common OAFs include interleukin-1 (IL-1), IL-6, macrophage inflammatory protein 1a, 6 parathyroid hormone-related protein, vascular endothelial growth factor (VEGF) 7 and ligands related to the tumor necrosis factor (TNF) superfamily. 8, 9 In return, osteoclasts stimulate tumor growth and spread. 10 In multiple myeloma which causes exclusively osteolytic bone lesions and thus acts as a model disease for cancerinduced bone destruction, the highest level of bone remodeling occurs notably in regions close to myeloma cell conglomerates. 11, 12 A major OAF, receptor activator of nuclear factor kappa B ligand (RANKL), which is a TNF family member, was found to be increased in the bone marrow microenvironment in multiple myeloma. 13, 14 It acts both through a transmembrane receptor RANK that is expressed on osteoclastic lineage cells. 15 A soluble decoy receptor for RANKL, osteoprotegerin 16 is expressed in osteoblasts 17 and stromal cells. 18 In osteoclasts, RANKL/RANK binding activates tumor necrosis factor receptor-associated factor 6 (TRAFs). Predominantly, TRAF6 19 activates consecutively downstream signaling that involves activation of c-Jun N-terminal kinase (JNK) and I-kB kinase (IKK). 20 IKK regulates the degradation of the inhibitor of nuclear factor kappa B (NF-kB), I-kB by promoting its phosphorylation and further degradation by the proteasomeubiquitin pathway. 21 In cytoplasm, the inactive NF-kB is bound to I-kB. 22 When I-kB becomes degraded, liberated NF-kB in consequence translocates into the nucleus where it binds to DNA and promotes the transcription of various genes encoding several survival and pro-proliferative proteins. 23 The first evidence for the activator protein-1 (AP-1) transcription factors c-Fos and c-Jun toward osteoclastogenesis was documented by c-Fos knockout mice which were shown to be osteopetrotic due to complete absence of osteoclasts. 24 c-Jun knockouts showed embryonic lethality and thus were unable to be examined. 25 When transcriptionally active, phosphorylated c-Jun associates with the Fos family members and both transactivate osteoclastspecific genes. 26 The p38 mitogen-activated protein kinase (MAPK) pathways predominantly have been shown to be activated in monocytic precursors upon RANKL, IL-1 and TNF-a stimulation. 27 Targeting the activation of p38 by the inhibitor SB203580 resulted in diminished osteoclast differentiation, 28 whereas the resorptional capacity remained unaffected. 27 The regulation of transcriptional activity of AP-1 and NF-kB transcription factors occurs, among others, by the proteasomeubiquitin system. The proteasomes are large, intracellular extralysosomal protease complexes that control the intracellular levels of several short-living proteins responsible for cell growth. 29 A constitutively increased proteasome activity was found in myeloma cells. Circulating proteasome levels were found to be an independent prognostic factor for survival in previously untreated patients with multiple myeloma. 30 Bortezomib (PS-341), 31 that is the first proteasome inhibitor approved by the Food and Drug Administration, was shown to induce the stabilization of I-kB, 32 c-Fos and c-Jun. 33, 34 In multiple myeloma, the major effects of bortezomib were contributed to the inhibition of NF-kB activation. 35 Furthermore, it was also shown that treatment with bortezomib induced AP-1 activation, 36,37 which presumably could have rather stimulatory effects on osteoclastogenesis. To specifically address the role of NF-kB in mediating osteoclastogenesis and to elucidate other N-kB-independent mechanisms that are caused by proteasome inhibition, we compared the effects of bortezomib to those caused by the IKK inhibitor PS-1145. PS-1145 blocks the IKK activity with IC 50 of 88 nM and other examined kinases by 4100 mM.
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According to Terpos et al., 39 treatment with bortezomib could significantly reduce serum levels of bone resorption markers TRACP5b and CTX in multiple myeloma patients, but it remained unclear whether this is due to a direct effect on osteoclasts or an indirect effect because of a reduction in the myeloma mass.
We hypothesized that the inhibition of NF-kB activation by selective IKK inhibition or by proteasomal inhibition might result in reduction of osteoclast differentiation and inhibition of bone resorption in a human osteoclast model. The Figure 1 shows the subcellular signaling of the RANKL/RANK axis in osteoclasts.
Materials and methods

Preparation of osteoclast progenitors and differentiation schedule
Preosteoclasts were derived from peripheral blood of healthy volunteers, both male and female, using the mononuclear cell fraction obtained by Ficoll-Hypaque density gradient (j ¼ 1.007) centrifugation. Targeted cells were stained immunomagnetically with a monoclonal anti-CD14 antibody, subsequently purified using a MACS-column (Miltenyi, Bergisch-Gladbach, Germany) and finally reseeded at a cell density of 2 Â 10 5 cells/cm 2 . The cell purity was tested by an anti-CD14/45 antibody (Becton Dickinson, Heidelberg, Germany). An isotype-matching anti-g1/g1 antibody (Becton Dickinson) served as a negative control. The osteoclastogenic medium consisted from 25 ng/ml RANKL, 25 ng/ml macrophage colony-stimulating factor (M-CSF) (PreProTech, London, UK), 10% fetal calf serum (FCS) (Biochrom, Berlin, Germany), 100 U/ml penicillin and 100 mg/ml streptomycin and minimal essential medium (Sigma-Aldrich Chemie, Taufkirchen, Germany). Cells were cultured in appropriate dishes up to 4 weeks, whereas the half media were replaced every 2-3 days. The experiments have been approved by the Ethics Committee of the University Hospital Charité Berlin in accordance with the Declaration of Helsinki. An informed consent was obtained from all volunteers.
Apoptotic effects of bortezomib and PS-1145 toward osteoclast precursors, preosteoclasts and mature osteoclasts Osteoclast precursors were generated as mentioned above. Cells were reseeded at a cell density of 2 Â 10 
Osteoclast differentiation assay
After purification, osteoclast precursors were seeded out at a density of 2 Â 10 5 cells/cm 2 in 96-well plates. Cells were differentiated for 1, 8 and 21 days, and than treated with the vehicle, bortezomib or PS-1145, as indicated. Thus, the treatment period of day þ 1 cells amounted 4 weeks, day þ 8 cells 3 weeks and day þ 21 cells 1 week. The half media containing the treatment drug were replaced three times per week. After a culture period of 28 days, cells were stained for tartrate-resistant acid phosphatase (TRAP) activity, using a commercially available Leukocyte Acid Phosphatase Kit (Sigma-Aldrich Chemie) according to the manufacturer's instructions. Mature osteoclasts were identified as large, TRAP þ cells containing more than two nuclei.
Osteoclast activity assays
The ability of osteoclasts generated from CD14 þ monocytic precursors to resorb bone was assessed using ivory dentine pits (German customs in accordance to international laws for the protection of species). Briefly, dentine slides were sterilized in 96% ethanol overnight, washed three times with sterile phosphate-buffered saline and incubated in FCS containing medium for 2 days to ensure the sterility. Preosteoclasts were cultured in osteoclastogenic medium, as described above, for 21 days. On the day þ 21, the treatment was started using both bortezomib and PS-1145, whereas the drugs were replaced every 2-3 days together with the medium. On the day þ 28, cells were lysed with a lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM ethylenediaminetetraacetic acid, 1 mM sodium orthovanadate and protease inhibitor cocktail Complete (Roche Molecular Biochemicals, Mannheim, Germany) for 30 min on ice, and total protein amounts were quantified using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA). Eventual remains were eliminated by hypochlorite. The media were collected and kept frozen at À801C until use. Pits were visualized by Toluidine blue staining and the resorption lacunae were quantified by light microscopy and Adobe Photoshop Version 8 software. Additionally, TRACP5b, that is an osteoclast-specific isoform of TRAP and thus a hallmark of osteoclast function, was measured from culture supernants (see below).
Transcription factor ELISA
In order to quantify the RANKL-induced NF-kB or AP-1 activation under different treatment schedules with bortezomib and PS-1145, we used enzyme-linked immunosorbent assay (ELISA)-based kits according to the manufacturer's instructions. Briefly, osteoclasts were processed on ice using the Nuclear Extract Kit (ActiveMotif, Rixensart, Belgium) and, subsequently, total protein amounts were quantified by BCA assay (Pierce). Using a provided 96-well plate that contained an immobilized oligonucleotide, which was specific for the target consensusbinding site, 3-5 mg of nuclear extract per well were allowed to react. Primary anti-NF-kBp65, c-Fos and phospho-c-Jun antibodies and an horseradish peroxidase-conjugated secondary antibody allowed a sensitive colorimetric readout.
Western blot
Osteoclasts were cultured for 21 days with support of RANKL and M-CSF, as described above. On day þ 21, the media were removed, cells were incubated in osteoclastogenic medium containing 25 ng/ml M-CSF and, in the treatment schedule, with 5 mM bortezomib or 10 mM PS-1145 for 60 or 90 min, respectively. Subsequently, 150 ng/ml RANKL or vehicle were added to the cultures and the samples were stimulated for 15 min. Afterwards, cells were subjected to nuclear and cytoplasmatic protein extraction, using Nuclear Extract Kit (Active Motif) according to the manufacturer's instructions. Nuclear proteins were subjected to transcription factor assays, as described above. Cytoplasmatic protein concentrations were quantified using the BCA assay (Pierce). Then, 30 mg protein/lanes were separated by a 10% gradient SDS-polyacrylamide gel electrophoresis (PAGE). After electrophoresis, the proteins were transferred to a polyvinylidene fluoride membrane (Bio-Rad, Munich, Germany), blocked in blocking buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20, 0.5% NP-40, 0.5% bovine serum albumin, 2.5% dry milk powder) at 41C overnight and subsequently incubated with the primary antibody at 41C overnight. As primary antibodies, monoclonal antibodies against phosphorylated I-kB (Cell Signaling Technology, Beverly, MA, USA), total I-kB (Santa Cruz Biotechnology, Heidelberg, Germany), h-RANK (R&D Systems GmbH, Wiesbaden, Germany), p38 and phosphorylated p38 (Cell Signaling Technology) were used. After thoroughly washing the membrane, it was incubated with appropriate peroxidase-conjugated secondary antibody at 41C overnight. The signals were detected by chemiluminescence using luminol (Santa Cruz Biotechnology). As an additional internal control, b-actin was detected with antib-actin antibody (Santa Cruz Biotechnology).
Measurement of VEGF and TRACP5b levels in cell culture supernatants
Cell pellets from osteoclasts grown on dentine pits were lysed and the protein contents were determined with BCA protein assay kit (Pierce). VEGF production was measured using a commercially available VEGF-ELISA (R&D Systems) according to the manufacturer's instructions. The osteoclast-specific TRAP (TRACP5b) activities were quantified using a Bone TRAP Assay (Immunodiagnostic Systems Ltd, Boldon, UK) according to the manufacturer's instructions. The tests were performed in two independent sets of experiments. Results of VEGF measurements were normalized to protein content.
Chemicals
Bortezomib and PS-1145 were kindly provided by Millennium Pharmaceuticals. Aliquots containing 1 and 10 mM were kept frozen at À801C until use.
Statistical analysis
Descriptive statistics and significance levels were determined using the SPSS Version 12.0 and Sigma Plot. The experiments were conducted in duplicate or triplicate and reproduced at least twice with similar results.
Results
Confirmation of osteoclastic lineage cells
After collection of MNC and after enrichment of CD14 þ cells, the purity was tested using a monoclonal anti-CD45/CD14 antibody and flow cytometry. The purity of sorted cells exceeded 97% (data not shown). To evolve osteoclasts, cells were cultured in presence of RANKL and M-CSF. We showed that the RANK expression increases with the increasing differentiation stage. Preosteoclasts on day þ 8 exhibit a weak RANK expression only, whereas day þ 21 osteoclasts strongly express RANK (data not shown).
Assessment of cytotoxicity of bortezomib and PS-1145 in different osteoclast differentiation stages
The first group of experiments was designed to investigate potential cytotoxic effects of bortezomib and PS-1145 in three different osteoclast differentiation stages. For this purpose, cells at the differentiation stage day þ 1, day þ 8 and day þ 21 were treated with either bortezomib, ranging from 0.01 to 100 nM, or with PS-1145, ranging from 0.01 to 100 mM. Interestingly, in the case of bortezomib, the cytotoxicity decreased with the increasing differentiation stage (Figure 2A ). The IC 50 for the day þ 1 cells was 9 nM, for the day þ 8 cells 32 nM and the IC 50 in day þ 21 cells was 92 nM. With regard to this finding, the concentration of bortezomib for the next group of experiments to investigate the inhibition of osteoclastogenesis and resorptional activity was fixed at sub-apoptotic levels by 0.1 and 1 nM. In the case of PS-1145, the highest sensitivity was found in day þ 8 cells ( Figure 2B ), with IC 50 of 100 mM, followed by 4100 mM in day þ 21 cells, and 4200 mM in day þ 1 cells. For the following group of experiments, the doses were fixed at 1 and Figure 2 Bortezomib and PS-1145 exhibit a dose-dependent growth inhibition and apoptosis. The drug doses that were chosen for further experiments considering osteoclast differentiation and resorptional activities were fixed at 0.1 and 1 nM bortezomib and 1 and 10 mM PS-1145. In (A) we show that the susceptibility to bortezomib (Btzmb) decreases with the increased differentiation stage. Black circles represent day þ 1 monocytic precursors, white circles day þ 8 preosteoclasts and day þ 21 osteoclasts are represented by black triangles. Day þ 8 preosteoclasts reveal the greatest susceptibility to PS-1145, followed by day þ 21 osteoclasts (B). The results were confirmed by a TUNEL assay ( Â 40 magnification); panel a represents a negative control (osteoclasts without any treatment) and panel b positive control (osteoclasts treated with 40 U/ml DNAse in order to induce apoptosis). The treatments were carried out with either 1 nM bortezomib (Btzmb) (c) or with 10 mM PS-1145 (d). As indicated by both MTT test and TUNEL assays, the selected doses for bortezomib were at sub-apoptotic concentrations, whereas for PS-1145 we chose one sub-apoptotic and one low-apoptotic concentration in the following experiments (C).
10 mM PS-1145 and corresponded to sub-apoptotic and lowapoptotic concentrations. As indicated by Figure 2C , 1 nM bortezomib failed to induce apoptosis in osteoclasts, whereas PS-1145 induced a weak apoptosis rate in osteoclasts at 10 mM.
Bortezomib and PS-1145 block maturation of osteoclasts
The next group of experiments was designed to assess the potentials of both drugs to inhibit osteoclast differentiation. Day þ 1, day þ 8 and day þ 21 cells were treated with 0.1 and 1 nM bortezomib and with 1 and 10 mM PS-1145 up to day þ 28. M-CSF and RANKL were added to the positive control and to treatment samples, whereas the negative control was stimulated by M-CSF only. As shown by TRAP/hematoxylin staining, the addition of RANKL led to appearance of giant, multinucleated cells (Figure 3a) . The addition of bortezomib and PS-1145 abrogated the RANKL-induced osteoclast differentiation in a dose-dependent manner (Po0.05 in all treatment schedules carried out from day þ 1 and day þ 8). As shown in Figure 3b , the effects were most striking when the treatment was carried out from the differentiation stage day þ 1. As expected, the treatment of differentiated osteoclasts from the day þ 21 (dark gray columns) was less effective in reduction of the number of multinucleated osteoclasts (Figure 3b ).
Effects of bortezomib and PS-1145 on resorptional activity
In order to evaluate the effects of bortezomib and PS-1145 toward osteoclast activity, we have generated mature osteoclasts on ivory pits put in 24-well plates. Osteoclasts were cultured up to 21 days in presence of RANKL and M-CSF. Finally, treatment schedule with 0.1 and 1 nM bortezomib and 1 and 10 mM PS-1145 was carried out for 1 following week. Both bortezomib and PS-1145 inhibited the activity of mature osteoclasts (Figure 4a ) in a dose-dependent manner. The quantification of resorption lacunae revealed that the dentine resorption was reduced by 65% for 0.1 nM bortezomib (Po0.01), by 79% for 1 nM bortezomib (Po0.0005), by 60% for 1 mM PS-1145 (Po0.05) and by 91% for 10 mM PS-1145 (Po0.0005) (Figure 4b ). Quantification of TRACP5b activity that represents a hallmark of osteoclastic function revealed a significant reduction of TRAP activity under treatment conditions (Figure 4c ).
Bortezomib and PS-1145 inhibit RANKL-induced NF-kB activation
In an effort to elucidate the molecular mechanisms underlying the inhibitory activity of bortezomib and PS-1145, we next examined the I-kB/NF-kB family members. In osteoclasts, the addition of RANKL induced the phosphorylation of I-kB and subsequent NF-kB activation in mature osteoclasts. According to Hideshima et al., 38 cells were pretreated with bortezomib and PS-1145 for 60 and 90 min before stimulation, respectively. In contrast to bortezomib that induced stabilization of phosphorylated I-kB, PS-1145 inhibited the phosphorylation of I-kB. In consequence, both drugs inhibited I-kB degradation by the proteasome and thus prevented NF-kB from translocation into the nucleus, a phenomenon that was reflected in diminished NF-kB binding activity (P ¼ 0.029) (Figure 5a ). In contrast to mature osteoclasts, this effect was not observed in preosteoclasts on the day þ 8 that exhibited only a weak RANK expression. Although bortezomib led to stabilization of phosphorylated I-kB, no loss of NF-kB p65 binding activity was observed. This implicates that in contrast to inducible NF-kB activity, the constitutive NF-kB p65 activity was not affected by bortezomib. PS-1145 also failed to inhibit the phosphorylation of I-kB and thus the NF-kB activation in day þ 8 cells (Figure 5e ). Figure 3 Bortezomib and PS-1145 inhibit osteoclast differentiation in a dose-and time dependent manner. In order to quantify the inhibition of osteoclastic differentiation induced by proteasome inhibition and IKK inhibition, cells were treated from the day þ 1, day þ 8 and day þ 21 of the culture up to day þ 28. Finally, cells were stained for TRAP-activity. In (a), the treatment was performed with 0.1 nM bortezomib (Btzmb) and 1 mM PS-1145 starting at day þ 1. Under both treatment conditions, the osteoclast differentiation was abrogated significantly without any visible reduction in cell density. Cells stimulated with 25 ng/ml macrophage colony-stimulating factor (M-CSF) alone served as a negative control (NC). Cells stimulated with both 25 ng/ml M-CSF and 25 ng/ml receptor activator of nuclear factor kappa B ligand (RANKL) served as a positive control (PC), as indicated by the appearance of large, multi-nucleated and TRAP-positive cells. (b) Shows time-and dose dependency of anti-osteoclastic treatments. Monocytes cultured with M-CSF only (native) served as negative control. In contrast, positive control and treatment schedules were both carried out in presence of M-CSF and RANKL. The efficacy of the treatment was greatest when treatment was started at day þ 1 (black columns) and decreased if treatment was carried out from the preosteoclastic differentiation stage day þ 8 (gray columns). As expected, the treatment of differentiated osteoclasts from the day þ 21 (dark gray columns) was less effective in reduction of the number of multinucleated osteoclasts. In the case of 10 mM PS-1145, some reductions in cell densities were observed, implicating that the inhibition of osteoclast differentiation partially was due to the low pro-apoptotic effect of the indicated doses.
The AP-1 pathway is negatively affected in osteoclasts, but positively affected in preosteoclasts during treatment with the proteasome inhibitor bortezomib
The next group of experiments was carried out to evaluate the effects of bortezomib toward AP-1 transcription factors c-Fos and c-Jun. The AP-1 family members are activated by TRAF-6 upon RANKL stimulation, which was also confirmed by our positive control sample (Figure 5b ) in receptor-bearing mature osteoclasts. In the osteoclast differentiation stage day þ 21, both bortezomib and PS-1145 could inhibit the RANKL-induced phosphorylation of c-Jun (Po0.05), whereas bortezomib increased the c-Fos levels (P ¼ 0.029); PS-1145 did not have any significant effects on c-Fos levels (Figure 5c ). In contrast, in day þ 8 preosteoclasts we did not observe any enhancement in AP-1 activation upon stimulation with RANKL (Figure 5f ). Interestingly, bortezomib led to stabilization of constitutive both c-Fos and phosphorylated c-Jun levels, whereas the levels of both AP-1 counterparts stayed unchanged when cells were pretreated with PS-1145 (Figures 5f and g ). All together, the data suggest that bortezomib might have, among negative effects considering other signaling pathways, positive effects toward AP-1 triggered early osteoclast differentiation; however, this effect was overcome by the blocking of the p38 pathway. This might be reflected in lower inhibitory levels of bortezomib toward osteoclast differentiation when compared to PS-1145. In contrast, in mature osteoclasts bortezomib could abrogate the RANKL-induced c-Jun phosphorylation and thus reduction of AP-1 activation that resulted in superior inhibition of osteoclast function when compared to osteoclast differentiation.
p38 MAPK signaling pathway is affected by bortezomib and PS-1145
The phosphorylation of p38 MAPK occurs upon M-CSF and RANKL stimulation in osteoclastic precursors and osteoclasts and was previously shown to be essential for osteoclastogenesis. 27 Therefore, to investigate further molecular mechanisms of bortezomib and PS-1145 on osteoclastogenesis, both preosteoclasts and osteoclasts were investigated for the expression levels of active, phosphorylated p38 and total p38. As presented in Figures 5d and h, we observed p38 phosphorylation in both day 8 and day 21 cells upon M-CSF and RANKL stimulation. These effects were abrogated by both bortezomib and PS-1145, independently of differentiation stage. Thus, these findings highlight the importance of p38 activation toward osteoclast differentiation and function and elucidate the mechanism of action of bortezomib in osteoclastic precursors and mature osteoclasts.
Bortezomib and PS-1145 reduce VEGF levels in culture supernants obtained from mature osteoclasts Figure 4 Bortezomib and PS-1145 inhibit osteoclastic dentine resorption. To examine the effects of bortezomib and PS-1145 on osteoclast function, cells were evolved with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B ligand (RANKL) on dentine pits up to mature osteoclasts (day þ 21) (a). Thereafter, the treatment with bortezomib or PS-1145 was started and carried out for 1 week. Osteoclasts stimulated with M-CSF only (NC, negative control) failed to resorb. Osteoclasts stimulated with M-CSF and RANKL (PC, positive control) were capable of resorbing the dentine by 495% surface area. Bortezomib (Btzmb) and PS-1145 both abrogated the dentine resorption dose dependently. The average resorption areas per experiment were quantified (b). The reduction of resorptional capacity partially correlated with the TRACP5b levels that were measured from the corresponding culture supernants (c). Figure 5 Receptor activator of nuclear factor kappa B ligand (RANKL)-induced signaling pathways affected by bortezomib and PS-1145. In (a) we show that RANKL induced nuclear factor kappa B (NF-kB) activation in day þ 21 osteoclasts upon RANKL stimulation (PC, positive control), which was due to enhanced I-kB degradation. Osteoclasts that were stimulated with macrophage colony-stimulating factor (M-CSF) only exhibited lower levels of NF-kB activity (NC, negative control). Both bortezomib (Btzmb) and PS-1145 inhibited the RANKL-induced NF-kB activation, whereas bortezomib inhibited the degradation of phosphorylated I-kB and PS-1145, the phosphorylation of I-kB that also resulted in diminished I-kB degradation. Furthermore, the phosphorylation and activation of c-Jun also occurred due to stimulation with RANKL (b). Both bortezomib and PS-1145 significantly inhibited the activation of c-Jun. In contrast, c-Fos levels were increased upon bortezomib treatment, whereas PS-1145 did not affect the c-Fos levels (c). However, for AP-1 activation, a dimerization of activated c-Jun and c-Fos is necessary. The phosphorylation of p38 MAPK kinase was affected by both drugs (d). In (e), we did not observe any further NF-kB activation upon RANKL stimulation in preosteoclasts day þ 8 due to weak RANK expression. Although bortezomib inhibited the degradation of phosphorylated I-kB, no inhibition of NF-kB activity was observed, indicating alternative pathways of constitutive NF-kB activation. PS-1145 failed to inhibit the NF-kB activation due to absent inhibition of constitutive IKK activity. In contrast to mature osteoclasts, RANKL stimulation failed to activate c-Jun in preosteoclasts (f). In that experiment, PS-1145 did not affect the AP-1 transcriptional factors, whereas bortezomib increased both phosphorylated c-Jun and c-Fos levels (f, g), which might result in constitutive AP-1 activation in preosteoclasts. The phosphorylation of p38 was diminished by both drugs equally (h). All together, the data demonstrate that osteoclast precursors are initially independent of AP-1 and NF-kB pathways. In that early differentiation stage, p38 MAPK signaling seems to be the crucial one for further osteoclastic cell development. At later differentiation stages, the RANKL-induced AP-1 and NF-kB activities rise with the RANK expression. The results of the experiments discussed in this figure show that proteasomal inhibition acts through MAPK inhibition in precursors and predominantly affects the osteoclast differentiation, whereas AP-1 and NF-kB pathways are affected at later differentiation stages and predominantly inhibit osteoclast activation and thus bone resorption. growth and neoangiogenesis are previously elucidated. Blocking the VEGF overproduction in multiple myeloma may represent a therapeutic approach. Thus, it was of interest if AP-1 inhibition could downregulate the osteoclastic VEGF secretion.
In our experiment, differentiated osteoclasts were treated with indicated doses of bortezomib and PS-1145 from day 21 to day 28 ( Figure 6 ). The quantification of VEGF secretion from culture supernants collected at the day þ 28 showed a dose-dependent inhibition of VEGF secretion. In contrast to PS-1145 that failed to inhibit the VEGF secretion at 1 mM (P ¼ 0.8), 10 mM PS-1145 and both dosing schedules of bortezomib significantly reduced the VEGF secretion of mature osteoclasts (Po0.05). Interestingly, the withdrawal of RANKL from day 21 to day 28 resulted in significant (P ¼ 0.02) reduction of VEGF secretion by osteoclasts, indicating that the stimulation with RANKL is essential for osteoclastic VEGF production.
Discussion
Bone is a dynamic organ which is continuously remodeled by resorption of primary bone and buildup of new bone, a process that physiologically requires exactly coordinated cross talks between bone-resorbing cells (osteoclasts) and bone-synthesizing cells (osteoblasts). 1 Osteolytic bone disease is a common manifestation in cancer, for example in multiple myeloma and breast cancer. 40 Cancer-induced bone disease can lead to severe bone pain, pathological fractures, symptoms of hypercalcemia and reduced quality of life. 3 Osteoclasts are terminally differentiated cells that evolve from monocyte/macrophage lineage. 41, 42 In malignant diseases, the enhanced osteoclast differentiation might occur due to enhanced chemotaxis of monocytic precursors and consecutive direct contact between tumor cells and osteoclastic lineage cells 43 or by stimulation by soluble, tumor-and microenvironment-secreted cytokines. 44, 45 One of the crucial cytokine systems that is involved in osteoclast differentiation in cancer was identified as a TNF-a superfamily member. 46, 47 It consists of an effector, RANKL, which acts upon the binding to its receptor RANK. The downstream signaling of RANKL involves the crucial pathways of osteoclast differentiation (Figure 1 ). Novel-targeted therapies that are based on the inhibition of proteasome-ubiquitin system have repetitively been shown to interact with NF-kB and AP-1 pathways. 48 However, the effects of proteasomal inhibition included the stabilization of c-Fos and c-Jun and it remained unclear if the proteasome inhibition was inferior to selective inhibition of NF-kB activation. Thus, the aim of this study was to elucidate the cellular and molecular effects of the clinically used proteasome inhibitor bortezomib and the selective IKK inhibitor PS-1145 in a human osteoclast model. First, we evaluated apoptotic and nonapoptotic doses of bortezomib and PS-1145, using MTT and TUNEL tests. Further studies were conduced at sub-apoptotic concentrations of bortezomib and at one subapoptotic and one low-apoptotic concentration of PS-1145. Interestingly, we showed that the susceptibility to both drugs depended on the osteoclast differentiation stage, whereas in the case of bortezomib, the toxicity decreased with the increasing differentiation stage. In contrast, PS-1145 exhibited the highest toxicity in intermediate differentiation stage, whereas the monocytic progenitors displayed the lowest susceptibility. The osteoclast differentiation was abrogated by both drugs, whereas the effects were most pronounced in the case of early treatment begin. At the day 21 of culture, the differentiation reached peak levels, thus no significant reduction in number of multinucleated osteoclasts could be further achieved. Bortezomib could significantly reduce the osteoclast differentiation, but the effects were slightly inferior to those achieved by PS-1145. To study the osteoclast resorptional activity, we used cells from the day þ 21 and treated them for 1 further week. Interestingly, the resorptional capacity was significantly decreased in all treatment schedules, whereas the effects of bortezomib were comparable to the effects of PS-1145. The analyses of the three crucial pathways of osteoclastogenesis which all are at least induced by M-CSF and/or RANKL stimulation elucidated that in early osteoclast precursors, the strongest mechanisms of action occurred due to the p38 MAPK inhibition which was observed after treatment with either bortezomib or PS-1145. In contrast to PS-1145, bortezomib positively regulated the AP-1 pathways in osteoclastic precursors, whereas both drugs inhibited the phosphorylation and activation of c-Jun at later differentiation stages. This might explain the observation that PS-1145 was slightly more effective toward inhibition of osteoclast differentiation, whereas the net inhibition of osteoclast function was comparable for both drugs. These findings were, at least partially, surprising, because we did not expect any inhibitory effects of PS-1145 on MAPK and JNK signaling. Recently, it was shown that c-Jun is an efficient substrate of IKKe, indicating that the c-Jun-activation does not exclusively occur by JNK in an IKK-independent pathway. 49 However, it remains unclear if the observed effects in our experiment were caused by reduced selectivity of PS-1145 at 10 mM or if there is a cross talk between the AP-1 and NF-kB pathways as previously described by the others. 50, 51 Interestingly, the NF-kB activation was observed at later differentiation stages only, probably due to the weak RANK expression on early osteoclast precursors. Therefore, a significant inhibition of RANKL-induced NF-kB activation was The expression and secretion of vascular endothelial growth factor (VEGF) levels. VEGF levels were measured from culture supernants collected at day þ 28, whereas the treatment period was started at day þ 21. Both doses of bortezomib (Btzmb) were sufficient to diminish the osteoclastic VEGF production. In contrast to 10 mM PS-1145, 1 mM PS-1145 failed to inhibit the VEGF production. NC (negative control) represents osteoclasts further stimulated with macrophage colony-stimulating factor (M-CSF) only, and PC (positive control) osteoclasts upon M-CSF and receptor activator of nuclear factor kappa B ligand (RANKL) stimulation.
observed in later differentiation stages, implicating a strong potential of NF-kB as target for the inhibition RANKL-induced osteoclastic bone resorption. In preosteoclasts, we did not observe any loss of constitutive NF-kB activity. VEGF, that is a transcriptional product of AP-1, 52 can promote tumor growth, 53 angiogenesis and osteoclastogenesis, 7, 44 implicating its promoting effects on vicious circle that exists between tumor cells, osteoclastic lineage cells and stromal cells. Thus, the aim of this part of our study was to elucidate if the AP-1 inhibition caused by bortezomib and PS-1145 resulted in diminished VEGF protein secretion by osteoclasts. In fact, under treatment conditions, we found reduced VEGF levels, whereas the effects were most pronounced in the bortezomib treatment schedules. Thus, inhibiting the osteoclastogenesis in an AP-1-dependent manner may not only inhibit the tumor-induced lytic bone disease, but could also have an impact on bone marrow angiogenesis and tumor growth.
In conclusion, our data demonstrate that bortezomib inhibited p38 MAPK-triggered early osteoclast differentiation, whereas the inhibition of later osteoclast differentation, osteoclast activation and resorptional activity occurred owing to inhibition of AP-1 and NF-kB activation. Altogether, these data build the framework for clinical use of bortezomib in cancer-induced lytic bone disease, especially in myeloma bone disease.
